Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Investor Presentation (November 2025)
35 slides from Cognition Therapeutics's investor presentation, November 2025
Slide 1: Zervimesine: a Once-daily Oral Therapeutic Advancing Towards Phase 3
Zervimesine: a Once-daily Oral Therapeutic Advancing Towards Phase 3 November 2025
Slide 2: Forward-looking Statements
Forward-looking Statements FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate t
Slide 3: Novel MoA Discovered Through Founder's Screening Assay
Novel MoA Discovered Through Founder’s Screening Assay Zervimesine Interrupts Binding of Toxic Oligomers • Phenotypic in vitro screen to select molecules that protection neurons from toxic oligomers • Screened 10,000 compounds through this assay and identified 5 unique chemical series • Zervimesine
Slide 4: Zervimesine (CT1812) – Lead Product Candidate
Zervimesine (CT1812) – Lead Product Candidate Extensive comp of matter IP on zervimesine and other candidates developed from foundational platform Zervimesine • BBB-penetrant small molecule oligomer antagonist PrPc lilrb2 • MoA: ligand of TMEM97 (sigma-2) receptor TMEM97 PGRMC1 • Oral, once-daily do
Slide 5: Findings from Completed Studies Support Phase 3 Plans
Findings from Completed Studies Support Phase 3 Plans Program Preclin Phase 1 Phase 2 Phase 3 Takeaways from completed studies • Phase 2 SHINE Study: Efficacy across Alzheimer’s disease Phase 2 COG0203 • START Early-to-mild Alzheimer’s disease cognitive measures in mild-to-moderate Alzheimer’s disea
Slide 6: Executive Program Summary
Executive Program Summary Compelling data with first-in-class candidate supports registrational plan • Consistent efficacy signals in Alzheimer’s, DLB and dry AMD - One of few compounds effective in both mild & moderate Alzheimer’s disease - GA lesion growth reduced with zervimesine treatment • Well
Slide 7: CGTX Company Summary: With Recent Raise, Advancing Towards Late-stage Studies
CGTX Company Summary: With Recent Raise, Advancing Towards Late-stage Studies Following EOP2 FDA Meeting 2025 Phase 2 DLB awarded CGTX regained Podium Presentation Nasdaq compliance at AAIC Jun Jul Aug Sep Oct Anonymous donor Alzheimer’s EOP2 FDA minutes confirm Close $30M Initiating required PK, fu
Slide 8: Alzheimer's Disease
Alzheimer’s Disease 95% slowing of cognitive decline in lower-p-tau217 'SHINE' participants
Slide 9: SHINE: Phase 2 PoC in Mild-to-Moderate Alzheimer's Disease
SHINE: Phase 2 PoC in Mild-to-Moderate Alzheimer’s Disease Well-executed, over-enrolled study, supports advancing clinical development Enrolled Population: Inclusion and Exclusion Treatment Period 6 months • PET- or biomarker-confirmed AD • AD diagnosis • Majority of participants were female • PET o
Slide 10: Up to 108% Percent Slowing on Assessments
Up to 108% Percent Slowing on Assessments Strong, consistent efficacy signals across measures Cognition Function ADAS-Cog 11 ADAS-Cog 13 MMSE ADCS-ADL ADCS-CGIC Zervimesine median Pooled p-tau217 95% 103% 108% 68% 61% (100/300mg) mITT 38% 39% 70% 26% 28% 10
Slide 11: Tau Burden in Amyloid-related AD Clinical Trials
Tau Burden in Amyloid-related AD Clinical Trials Baseline plasma p-tau217: a predictive biomarker of response to therapy • Plasma p-tau217 reflects brain amyloid and tau burden • Prior data indicate that individuals with lower AD pathology at baseline, as reflected by lower levels of plasma p-tau217
Slide 12: Participants with Below Median p-tau217 Experienced Profound Treatment Effect
Participants with Below Median p-tau217 Experienced Profound Treatment Effect Preservation of ADAS-Cog 11 in participants below median plasma p-tau217† ADAS-Cog 11* mITT population (n=150) Below median p-tau217 (n=69) -2.0 -3.0 38% slowing 95% slowing -2.0 -1.0 LS Mean (SE) Change from Baseline LS M
Slide 13: Consistent Treatment Impact in Participants with Lower p-tau217 Across Baseline MMSE scores
Consistent Treatment Impact in Participants with Lower p-tau217 Across Baseline MMSE scores Cognitive preservation (ADAS-Cog 11) observed across MMSE range Zervimesine-Treated Mild (MMSE 22-26) Zervimesine-Treated Moderate (MMSE 18-21) Participants -4.0 -5.0 129% slowing -4.0 91% slowing -3.0 -3.0 L
Slide 14: Participants Evenly Distributed by Median p-tau217 and MMSE Severity
Participants Evenly Distributed by Median p-tau217 and MMSE Severity MMSE at Screening vs p-tau217 at Baseline in SHINE Mild MMSE Moderate MMSE Median MMSE Plasma pTau-217 at Baseline 3- Median plasma p-tau217 Baseline Plasma p-tau217 2- MMSE at Below Above Total Screening Median Median Mild (22-26)
Slide 15: FDA Confirms Phase 3 Plan in Alzheimer's Disease
FDA Confirms Phase 3 Plan in Alzheimer’s Disease Alignment reached with FDA during end-of-Phase 2 meeting • End-of-Phase 2 meeting conducted July 9, 2025 • FDA minutes received August 12, 2025 - Aligned on following design: • Disease stage: Adults with mild-to-moderate Alzheimer’s disease • Biomarke
Slide 16: START – Phase 2 Early AD Study Reaches 75% Enrollment
START – Phase 2 Early AD Study Reaches 75% Enrollment First study to allow lecanemab as background therapy in combination with zervimesine Enrollment Treatment Period Program Assessments Criteria 18 months Objectives ‐ Ages 50-85 ‐ Safety Identify efficacy Zervimesine 200 mg signal(s) ‐ Diagnosis
Slide 17: Dementia Programs
Dementia Programs: Strong clinical signals in the two primary causes of dementia: Dementia with Lewy Bodies (DLB) Mild-to-Moderate Alzheimer’s Disease
Slide 18: AD and DLB: Diseases with Overlapping Pathology
AD and DLB: 2 Diseases with Overlapping Pathology Primary treatment goal – slow the progression of cognitive decline • Aβ: closely associated with Alzheimer’s pathogenesis Amyloid • α-synuclein: closely associated with Lewy body dementias beta (Aβ) • Co-pathology is common - Up to 80% of DLB patient
Slide 19: Dementia with Lewy Bodies (DLB)
Dementia with Lewy Bodies (DLB) Strong clinical signals across four major symptom domains in Phase 2 SHIMMER Study
Slide 20: SHIMMER Study in Dementia with Lewy Bodies
SHIMMER Study in Dementia with Lewy Bodies Conducted in collaboration with experts at LBDA and University of Miami Enrollment Treatment Period Program Assessments Criteria 6 months Objectives ‐ Age 50-85 ‐ Safety/tolerability Identify efficacy Zervimesine 300 mg 130 ‐ Global CGIC signal(s) ‐ DLB d
Slide 21: Up to 91% Percent Slowing on Assessments
Up to 91% Percent Slowing on Assessments Strong clinical signals across major DLB symptoms relative to placebo Behavior Cognition Function Movement CDR NPI NPI (episodic MoCA CAF ADCS-ADL UPDRS (total) (distress) memory) Zervimesine Pooled (100/300mg) 86% 114% 85% 60% 91% 52% 62% 25 * Measure of the
Slide 22: Zervimesine Showed Dramatic 86% Impact on Neuropsychiatric Measures
Zervimesine Showed Dramatic 86% Impact on Neuropsychiatric Measures NPI captures a variety of patient disturbances, including hallucinations, anxiety, and delusions NPI NPI favor Treatment with Zervimesine NPI Total Score (A-L) 86% Slowing LS Mean Difference from Placebo 95% CI Anxiety Delusions Hal
Slide 23: Participants Improved in Hallucinations, Delusions & Anxiety, Caregivers Better
Because Participants Improved in Hallucinations, Delusions & Anxiety, Caregivers were Notably Better New tool created to measure caregiver burden in DLB NPI Distress NPI Distress favors Treatment with Zervimesine NPI Total Score (A-L) Caregiver Distress 114% Slowing LS Mean Difference from Placebo 9
Slide 24: Up to 91% Slowing of Cognitive Decline Across Assessments
Up to 91% Slowing of Cognitive Decline Across Assessments CT1812 100mg (n=44) CT1812 300mg (n=44) Zervimesine improved patients’ attentiveness and problem solving Placebo (n=42) MoCA (ITT) CDR - Episodic Memory (ITT) CAF (Fluctuations) (ITT) 2.0 10.0 -2.0 5.0 -1.5 1.0 LS Mean (SE) Change from Baseli
Slide 25: People on Zervimesine Maintained Self-care
People on Zervimesine Maintained Self-care 52% preservation in activities of daily living (ADL) measures ADCS-ADL 52% slowing 2.0 Components 0.0 of ADL Score LS Mean (SE) Change from Baseline -2.0 -4.0 Bathing Toileting Worsening -6.0 Dressing Conversing -8.0 CT1812 100 mg (n=44) -10.0 CT1812 300 mg
Slide 26: People Treated with Zervimesine Maintained Motor Function
People Treated with Zervimesine Maintained Motor Function 62% preservation in measures of movement MDS-UPDRS3 62% slowing Components -4.0 of UPDRS: -2.0 LS Mean (SE) Change from Baseline 0.0 Balance Gait Worsening 2.0 4.0 Speech Facial expression CT1812 100 mg (n=44) 6.0 CT1812 300 mg (n=44) Placebo
Slide 27: Summary of SHIMMER Safety and Tolerability findings
Summary of SHIMMER Safety and Tolerability findings Favorable safety profile, AEs balanced between arms – Consistent with SHINE Results Total AE frequency was similar There were no deaths related Participants with LFT elevations in CT1812 and placebo to study drug ≥ 3x ULN • 100mg CT1812 – 3 •
Slide 28: MAGNIFY Topline Results
MAGNIFY Topline Results GA lesion growth slower with zervimesine treatment
Slide 29: MAGNIFY Trial in Dry AMD/GA
MAGNIFY Trial in Dry AMD/GA Zervimesine: oral drug development candidate for geographic atrophy Enrollment Treatment Period Program Assessments Criteria 24 months Objectives ‐ Age: ≥ 50 ‐ Change in GA lesion ‐ Identify efficacy ‐ Diagnosis of dry AMD area (FAF) signal(s) Zervimesine 200 mg Adults wi
Slide 30: Zervimesine Treatment Slowed GA Lesion Growth
Zervimesine Treatment Slowed GA Lesion Growth Effect size increases with exposure • 29% mean rate of change (slope) in GA lesion area vs placebo (p=0.0538) • Change in GA progression rate favored zervimesine vs placebo at each timepoint - 6-months: -11.79% - 12-months: -15.83% - 18-months: -28.19% (
Slide 31: Zervimesine Slowed GA Lesion Growth Rate (slope) and Area (observed)
Zervimesine Slowed GA Lesion Growth Rate (slope) and Area (observed) Slope Analysis1 Mean Area by Time1 3 P = 0.0074 2.5 Zervimesine Placebo Diff LS Mean Change from Baseline in zervimesine GA lesion size (mm2 ) by FAF placebo 2 Growth rate 0.10 0.14 - 0.04 1.5 (mm2 / month) ± 0.015 ± 0.014 1 Annual
Slide 32: Zervimesine Effect Size Comparable to SoC IVT with Oral Once-Daily Dosing
Zervimesine Effect Size Comparable to SoC IVT with Oral Once-Daily Dosing Topline MAGNIFY Results3 Compared to Published Results1,2: Percent Reduction in GA Lesion Growth Over Time 35% IZERVAY Avacincaptad pegol (2mg)1 28% Percent Difference from Placebo 30% • Gather1 at 18 months – 35% • Gather2 at
Slide 33: 3 Major Diseases Addressed with Once-Daily Oral Pill
3 Major Diseases Addressed with Once-Daily Oral Pill Collective Phase 2 Results Supports Advancing Zervimesine (CT1812) to Registrational Studies Dementia with Alzheimer’s Disease Geographic Atrophy Lewy Bodies Marked slowing of progression Slowing of progression; robust Slowing of GA growth across
Slide 34: Current Financial Position
$30 Million Equity Raise Closed August 2025 Current Financial Position As of quarter ended September 30, 2025 Cash and cash equivalents $ 39.3 M Grant funding for zervimesine studies Preclinical through Phase 2 ~$171 M Approximate funding used ($135 M) Remaining grant funding $36 M 41
Slide 35: Thank You
Thank You Lisa Ricciardi President & CEO info@cogrx.com
Cognition Therapeutics — Investor Presentation (November 2025) on 6ix